Photo showing the Sigi patch pump, Tslim X2 pump and Mobi pump with iPhone


Tandem Diabetes has made some big moves recently, acquiring two new companies – one makes infusion sets, the other a patch pump called Sigi, and their tiny Mobi pump is in front of the FDA right now. We’re finding out how it may all come together from Tandem’s EVP and Chief Strategy Office Elizabeth Gasser. We talk about how these acquisitions have changed Tandem’s road map – you may remember they released that look into the future last year – G7 integration, software updates and a lot more.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

2022 Episode with Tandem, includes links to the original 5-year road map

Please visit our Sponsors & Partners – they help make the show possible!

Take Control with Afrezza 

Omnipod – Simplify Life

Learn about Dexcom 

Check out VIVI Cap to protect your insulin from extreme temperatures

Learn more about AG1 from Athletic Greens 

Drive research that matters through the T1D Exchange

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

Sign up for our newsletter here

Here’s where to find us:

Facebook (Group)

Facebook (Page)



Check out Stacey’s books!

Learn more about everything at our home page 

Reach out with questions or comments:

Episode Transcription:

Stacey Simms 0:00
Diabetes Connections is brought to you by: The only ultra rapid acting inhaled insulin, by Dexcom, keeping you in control with an integrated system for diabetes management, and by T1D Exchange dedicated to improving outcomes for the entire T1D population.
This is Diabetes Connections with Stacey Simms.
This week, Tandem diabetes has made some big moves recently acquiring two new companies. One makes infusion sets the other a patch pump called Sigi, and Tandem’s tiny Mobi pump is in front of the FDA right now. We’re finding out how it may all come together.

Liz Gasser 0:45
Mobi will be here sooner than Sigi will be here. Mobi is as I said, a 23 product for us. Sigi sits a little bit further out we still need to go through further development. And obviously we’ll have to get through our own regulatory process with Sigi further down the road. So they exist side by side they serve slightly different needs.

Stacey Simms 1:04
That’s Tandem Executive Vice President and Chief Strategy Officer Elizabeth Gasser. We talk about how these acquisitions have changed tandems roadmap, you may remember they released that look into the future last year. We also find out more about Dexcom G7 integration, software updates and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Welcome to another week of the show. You know I’m always so glad to have you here. And we aim to educate and inspire about diabetes with a focus on people who use insulin. I’m your host, Stacey Simms and you know after a few years of what seemed like, frankly, not a lot of progress at all, I feel like we’re getting some big moves now. Right I mean, not just from FDA approvals, which are seem to be digging out from that big slowdown that happened during the first two years of COVID but also through some big company moves.
Last year Tandem diabetes acquired capillary biomedical, which makes infusion sets and they also purchased AMF medical, which makes the Sigi pump. It’s important to note that neither acquired company has a commercially released product. These are all in development. I spoke to the folks at Sigi I guess the folks at AMS medical that makes the Sigi pump. I spoke to them last year right around this time, they had received breakthrough device designation from the US FDA not approved still a long way from that, but it was really interesting to talk to them. And I will link up that episode in the show notes for this one. Of course we’re going to talk about it more today as well.
I spoke to this week’s guest tandems EVP and Chief Strategy Officer Elizabeth Gasser last year around this time as well, that interview was in January of 2022. And I’m going to link that episode up. If you go in there you can see the really interesting links that they gave us the roadmap that we talked about the five year plan for Tandem diabetes graphics and the announcement video. So knowing that things are going to change now with these acquisitions and other changes that happened. I was really glad that Elizabeth Gasser she says call her Liz. So I do. I was really glad that Liz decided to come back on. As usual, I brought as many questions to her as I could, including what’s happening with Dexcom G7. And their reaction to the tide pool loop approval. So a lot to talk about, and that’s coming up.
But first Diabetes Connections is brought to you by Afrezza. And when it comes right down to it, there hasn’t been a lot of innovation for insulin. I mean, there are different brands right but nothing really unique when it comes to insulin delivery, except for Afrezza is unique because it is the only Ultra rapid acting inhaled insulin available. It starts working quickly without the need for injections at mealtime. Once you breathe Afrezza into your lungs using the inhaler. Insulin appears in your bloodstream in less than one minute and it may start reducing blood sugar in about 12 minutes. Find out more and see if Afrezza is right for you. Go to diabetes and click on the Afrezza logo. Afrezza can cause serious side effects including sudden lung problems and low potassium is not for patients with chronic lung disease such as asthma or COPD or for patients allergic to insulin. Tell your doctor if you ever smoked I’ve ever had kidney or liver problems history of lung cancer if you’re pregnant or breastfeeding most common side effects are low blood sugar, cough and sore throat severe low blood sugar can be fatal. Do not replace long acting insulin with Afrezza a phrase is not for us to treat diabetic ketoacidosis please see full prescribing information including box warning medication guide and instructions for use at
Liz, thank you so much for joining me. We have a lot to get through. But thank you so much for jumping on the show and spending some time with me and my listeners. I appreciate it.
Liz Gasser 4:39
My pleasure. It’s always fun to talk with you, Stacy.
Stacey Simms 4:42
Thank you so much. That’s great to hear. I love learning about what’s going on in the technology part of the diabetes community. So I have a laundry list of questions. Let me just jump in and my listeners sent in a lot of these. So this is Top of Mind with the community as I’m sure you know, there’s so much going on at Tandem right now. But first Can you talk a little bit about integration with Dexcom? G7, they told us they’re going to launch in the United States sometime during the first quarter. So that clock is ticking. Can you talk about integration with the latest version of Dexcom?

Liz Gasser 5:13
Absolutely. And this is something we’ve been working on for a while, as you know, we’ve got a long history of working with Dexcom. And G7, at this point, represents our fourth integration with G4, G5 GSix, and now G7. The teams are working well together. Obviously, there’s a lot to do when you’re integrating a new sensor, the variety of development and testing efforts. In some markets, we will obviously have to go through some regulatory milestones as well to bring it to market. But we still continue to anticipate coming to market fairly soon after the G7 launches. Here in the US, our current goal is to be in market within one to two quarters. As I said, the timing depends on a number of things. What I would want your your listeners to know, though, is, obviously until we announced that it’s integrated, please don’t upgrade to the G7 and expect it to work with the T slim, we obviously need to make sure it’s validated and in market, but we’re working hard. And we’re excited to bring it to all of our customers.

Stacey Simms 6:16
If someone tried to do that. There’s not even I don’t know, is there a sensor numbers or transmitter number on the G7? It just would not. I assume that the T slim x two just would not take that

Liz Gasser 6:26
as won’t pair with it. What we need to do when we’ve finished the integration, we will push a software update, which will allow the T slim to add G7 support. And then you compare a G7 sensor with it

Stacey Simms 6:39
is the idea to be able as the user to choose either the G6 or the G7 would you be able to go back and forth?

Liz Gasser 6:45
Absolutely. That is exactly what we intend to do. That strikes me

Stacey Simms 6:49
as the first time. I mean, we get all excited about interoperability, Liz, but it strikes me is the first time maybe that people will be able to choose their CGM without changing their pump even though it’s the same brand of CGM.

Liz Gasser 7:03
That’s absolutely right. And that’s the beauty of being able to do this through a software update. We can implement it as a menu option on the pump.

Stacey Simms 7:10
Are there any other changes that would come from that Dexcom integration? Are there features or anything? Or is it just the you’d get the benefits of what’s in the G7 itself,

Liz Gasser 7:22
or what we tend to do is we target the integrations to come with a software release. And so there will be no other feature improvements that we strive to make with every major new software release for the pump. But the focus of the release will very much be on the G7 integration.

Stacey Simms 7:38
Got it? Can you share any of the software improvements? I know people have been talking about some adjustments, perhaps to control IQ to make it more aggressive in some ways.

Liz Gasser 7:47
We’re always looking at where we can make improvements. The release that is coming out with G7. There’s not explicitly a control IQ update release, we can talk about the various feature improvements, we are making control IQ. But that’s not the focus for this upcoming release.

Stacey Simms 8:01
Is that sooner than the G7 update, you think, or is that something’s down the road?

Liz Gasser 8:05
No, it’s down the road. We have an ongoing program to continue to refine the control IQ feature set. We’re working on greater personalization.

Stacey Simms 8:14
Let’s talk about something that happened a couple of weeks ago, and that is the acquisition of MF the company that makes the Sigi pump. What is the thinking behind this acquisition? This is so interesting. The Sigi is a patch pump, right?

Liz Gasser 8:29
That’s absolutely right. It’s a tubeless patch pump. Yeah. That’s very exciting for us. Well,

Stacey Simms 8:36
it is. It’s very interesting. It’s very exciting. A year or two ago, Tandem laid out a really ambitious roadmap for different pumps and working toward a patch pump. Eventually, I assume this means that it’s going to perhaps come in the plan sooner does it supplant the pump that we had talked about a year ago? Can you tell me a little bit more about what your plans are for Sigi?

Liz Gasser 8:57
Happy to? Absolutely. And I’m glad that you brought up the roadmap presentation that we gave about a year ago now, because we did at that time say that our intention was very explicitly to bring a portfolio of devices to market including a tubeless patch option. Because we do believe deeply that there is no one size fits all in diabetes, we do believe very much in offering choice, including as we’ve just talked about, with multiple generations of CGM. And so we were looking at how we could do that for our customers for for the people who use our pumps. And we did have an internal program that we were pursuing in parallel. But we were also talking to a number of third party companies who were building their own devices, including AMF medical with the CD pump. And we did ultimately decide that the better path for us was to pursue an acquisition and in large part that it’s got a lot to do with with the device itself or the Sigi pump.
It’s been fully designed, it’s small, it’s ergonomic for us, you know, as well, we very much believe in bringing better design to our users. And it’s something that’s that’s widely lacking in med tech or has been for decades. And it’s something that’s at the core of tandems DNA starting with the x two. And so we fell in love with the device itself. As I said, it’s a fabulous small pump. But we also as we went through the process of considering how we bring the right products to market really started to appreciate the advantages of this pump in particular, is obviously highly wearable. But it also is, it’s a prefilled pump, there’s no other patch out there, quite like it. But the intention is to use prefilled insulin cartridges to really improve the ease of filling and putting the pump on. So instead of you know, filling the cartridge and priming the tubing, you’ll you’ll pop the cap off, you’ll pop the cartridge in click SNAP, though, right, so very much focused on simplicity and ease of use there. And then the other thing that we had to confront, as we were thinking about what we did next was, you know, the program we had internally was pointed at delivering a disposable. And we really paused and said, Okay, well, we’re a durable device company. And we’re in the durable space today, because we really do believe in minimizing the waste that’s associated with the products that we bring to market. And so the lovely thing about the Sigi pump is it’s a durable pump, it’s not disposable, so we’re not wasting electronics, we’re not throwing away electronics every few days. And by that I mean batteries and you know Bluetooth chips to that through which we get conductivity. But then it’s also detachable, because it’s a durable system, you have an it’s a two part system, right? You have an onboarding site, and then the pump itself comes off. And the nice benefit of that is you’re not losing insulin, when life gets in the way you can take it off without wasting the insulin that’s been filled into the pump, there was a lot of advantages to the product, we also fell in love with the team. They’re very strong. There’s very strong cultural alignment between us and the team in Switzerland. We come from a very similar design philosophy. And obviously, as you know, Switzerland is it’s got a world renowned reputation for making small precise devices. Really, it all came together in the middle of last year. And we did ultimately decide to suspend our own internal patch development program in favor of pursuing this option.

Stacey Simms 12:30
I spoke to the folks at Sigi a while back and as you listen, I will link up that episode if you really want to get a deep dive into what this product is. But Liz, one thing that really stands out to me, as you already mentioned, not to put too fine a point on it is that it is not a disposable pump. People are used to thinking of patch pumps as you use them once and throw them away. As you listen, I’ll try to describe it the infusion set like a tube pump stays on the body. But the pump you get at least in the first iteration from Sigi. They had said you’d get two pumps so you could recharge one while the other one was on your body and then switch them out. When was my son’s tube pump he can take that off in lots of situations. That’s one of the reasons why he really likes it. Can the Sigi pump be removed for things like sports and stuff like that, or you only remove it when you change it?

Liz Gasser 13:14
No, it can be taken off the off the body patch. And so that’s that’s a big part of the appeal, as you say, when you need to take it off, you can take it off without wasting the insulin, and then you can put it right back on again.

Stacey Simms 13:24
So interesting. We we also talked during that roadmap conversation about the Mobi pump, which is not completely tubeless. There’s a small tube on it, I believe that has been filed for FDA approval, any changes, then in the short term, or the long term for the movie pump?

Liz Gasser 13:40
No, we’re still committed to bringing the movie pump to market. And that’s something that we are planning to bring to market in the latter part of 2023. As you said, we’ve submitted it to the FDA, we did that late last year. And we’re in the process of active conversation with them. As you know, it’s a dialogue. It’s a process, they have some feedback for us as we go through their approval cycle. And so we remain excited to bring this to patients, I think the best way to think about the two different pumps is and as I said they’re part of a portfolio. Mobi will be here sooner than Sigi will be here. Mobius, as I said, a 23 product for us seeking sits a little bit further out, we still need to go through further development. And obviously we’ll have to get through our own regulatory process with Sigi further down the road. And so they exist side by side, they serve slightly different needs. There’s as we’ve just discussed, Sigi is very much designed for tubeless where it’s tubeless only, whereas with Mobi it’s a tube pump which comes with different considerations, certainly, and flexibility of wear options. Obviously there’s there’s a smaller body footprint with some of the infusion set options that we have. And really it’ll be a continuum between the two devices.

Stacey Simms 14:50
I know when something’s from the FDA, you kind of are often limited on what you can say, but did anything change from what we talked about with Mo Be what was publicly released to when it was given to the FDA.

Liz Gasser 15:04
As we talked about a year ago, it really is it’s consistent with what we talked about. It’s a pump that’s fully controlled by the smartphone. It is a 200 unit pump, small form factor, wireless charging, waterproof and with the diversity of infusion set options that come with it, including a short five inch set that is facilitates different on Bodywear options.

Stacey Simms 15:29
When you talk about fully controlled by the phone right now the mobile bolus function, which I gotta say my son absolutely loves, although he did want me to tell you, he thinks there’s too much security. I said they probably can’t do a lot about that right now. But he said, you know, why does have to read my face every single time I use it. I said I would let you know that he thinks there should be less security. But the Mobi needs, as you said full phone functionality. When that comes. Do you anticipate it also coming for the T slim x two would that be at the same time?

Liz Gasser 16:00
I definitely know that there’s a request from from our customer base for more control options with the mobile bolus app but t slim. The focus with the Mobi app release will be on full control for mobi. But we do continue to look at how to bring some of those features back to the T slim x two. So it won’t be in the Mobi app, because that will be for the Mobi pump. But as we look at the mobile bolus app roadmap, you know, we were certainly aware of of user requests to do more, you know, including things like clearing alarms,

Stacey Simms 16:33
gone. Yeah. And that makes sense, too. I wasn’t thinking that way. There would be one app for mobi and one app for control of the T slim pump. No comment on Benny’s idea of less security for everyone.

Liz Gasser 16:45
I’ll make sure that our engineering and product teams here

Stacey Simms 16:50
needs a special team settings. That’s another story altogether. You’ve mentioned infusion sets a couple of times. Let’s talk about that. Let’s talk about capillary biomedical. This is another company acquired not too long ago, I get very excited when I hear about any improvement was infusion sets. My son has worn a pump. Since 2007. The weak link of every system has been how it connects to the body. There aren’t enough options. None of them seem to work that well. They don’t last long enough, I could go on and talk to you about this acquisition and what they do what they offer.
Right back to our interview, we’ll start talking about those new acquisitions by Tandem. But first Diabetes Connections is brought to you by Dexcom. And we have used Dexcom for so long now that it is hard to remember what it was like before we started right. I mean, I haven’t exactly forgotten because boy was a lot of work. But it is so different. Now, when he was diagnosed right before he turned two. And we were doing something like 10 finger sticks a day, at least even when he was a little older. We still did at least six to eight every day. And of course more when he wasn’t feeling well. But with each iteration of Dexcom. We have done fewer and fewer finger sticks the latest generation the Dexcom G6 eliminates finger sticks for calibration and diabetes treatment decisions. Just thinking about Benny’s little worn out fingertips makes me so glad that Dexcom has helped us come so far. He didn’t start using until he was nine years old and his fingertips are healthy and smooth, which I honestly never thought would happen when he was in preschool. If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. learn more go to diabetes and click on the Dexcom logo.
Now back to Liz Gasser talking about the newest acquisitions by Tandem.

Liz Gasser 18:44
Happy to and as you said we did two acquisitions in the last year, which is it’s a it’s it’s quite a quite something that’s quite a lot. So Cal bio as you say, capillary bio maker of an infusion sets specifically an extended wear infusion set. They also have a novel cannula technology. And so our focus there is look we hear you we see user feedback on on infusion sets all the time. And yes, as you say we need to make it easier to put on it easier to wear need to help people wear it for longer we need to reduce waste. Those are all focuses of our infusion set program and and for us. We work with partners today we have worked with with partners for many years. You know what led us to capillary BIOS they’ve been working on an extended seven day were set. We are excited to take that forward and move that into clinical trial in the year ahead. As I said the cannula itself is also novel. It’s designed to be significantly more resistant to kinking such that we can help with improve sight integrity, but also fewer occlusions and occlusion alerts. And so really it’s a it’s a great technology package. We’re still working to bring it to market it won’t be commercial For a little while, but we’re hopeful it can deliver meaningful benefits to our customers. Probably

Stacey Simms 20:04
a dumb question. Does it need FDA approval? Is it? Or Is any of this already FDA approved?

Liz Gasser 20:09
It will need an FDA submission

Stacey Simms 20:11
with the Mobi and with Sigi and with T slim, I mean this, you look at the myriad of infusion sets that you might need. I mean, could they all be interchangeable? Is that one of the goals? Or would you make you know, several different infusion sets for each pump? I’m just trying to picture how it would work?

Liz Gasser 20:26
Well, is it yes, there’s clearly a there’s a product strategy and packaging question in there, and it’s something we’ll we’ll need to work through. But right now that the intent is that we have a port, we will have a portfolio of tubed pumps, those have our as your familiar our hotteok connector on them. And then for all of the infusion sets that we offer, the goal is for interchangeability and mix and match. Now, will every infusion set work with every pump, I think we’ll need to work through that there may be some different labeling for different systems. But the goal is to have a diversity of infusion set options and a portfolio of pumps and allow people to mix and match for the choices that makes sense to them. Yeah,

Stacey Simms 21:12
it always amazes me that the infusion set company, I’ve talked to them before on the podcast, they make the infusion sets for so many different pumps, not just in the United States. And it’s almost like oh, you know, there is no one size fits all, but they tried to do their best to make it that way. So I’m really heartened and excited to see what comes out of this. Because, as I said, it’s one of those issues that we all have seen real problems over the years and not a lot of you know, all due respect to you know, medical, but it doesn’t seem like there’s been a lot of changes made or you know, a lot of strides forward. So I’m really excited to see what happens here. I did reach out to capillary biomedical when the announcement came through. And they they turned me down flat. So I’ve just circled back and see when they when you all get this together. Let’s have a more in depth conversation about not many other people want to talk about the deep dive of an infusion set, but you know, we would like to.

Liz Gasser 22:04
Absolutely. We’ll be back quit and in about a year with another episode. Stacey.

Stacey Simms 22:09
Yeah, that would be great. Sooner or sooner. You know, you mentioned you mentioned Mobi as a 2023 product. So maybe sooner deal. Excellent. I love it. You had mentioned and again, as you listen, you know, we’re trying to get through a lot here. So I know you want me to probably go more in depth on more things. But I’m doing my best here. You had mentioned a little bit of control IQ and adjustments in software updates. Could you speak for just a moment about any changes, because I hear from listeners all the time control qubit came out in 2020. We do love the system. But many people including myself, I’ll put myself in there really my son would like some more maybe aggressive settings, things like a perhaps lower range or more auto bolus power. Can you speak to any specifics coming to control IQ,

Liz Gasser 22:58
I’m not going to get too deep into the end to the specifics, because we have we have a little bit of sequencing that we’re doing with with our feature roadmap here, what I will say is, in the very near term, the immediate focus is on making sure we can get expanded indications. And so that means being able to bring it to a broader section of the peds community h2 plus. And then we’re also looking at making sure that we are indicated for for type two as well, so that we can allow more type twos to to benefit from our pump and from control IQ. As you know, we can’t actively market control IQ to type two today without an indication. So that’s phase one for us. And then phase two, really looking at greater personalization, ease of use usability, looking at lower ranges as part of that. But obviously, there’s a number of other features that we’re seeking to bring to market as well. And so we’re really taking our time just to see what the right combination is at the right time. So I know you want me to say more. Unfortunately, we’re gonna have to leave that one.

Stacey Simms 24:00
I will tell you though, Liz, I’m very heartened to hear so much more attention paid to people with type two and getting more access to insulin pumps and automated systems. I saw a study recently and forgive me, I don’t remember which pump it was or if they said, but it showed something like when people with type two started an automated system. They spent eight hours more a day in range. Now I’m taking this from memory. So I’ll look it up. And I’ll link it up when the episode comes out. But I assume you’ve already done a lot of studies with folks with type two and are you able to share? Have you seen some of those similar results? They’re just to be so much better,

Liz Gasser 24:33
but absolutely agree with you. We have real world data of people with type two on our pumps who have been prescribed by their physician. We’ve also been doing studies and I agree with you that the benefits are immediate and they are sustained and they are meaningful. People with type two benefit on insulin intensive therapy benefit just as much from automated algorithms as people with type one.

Stacey Simms 24:55
I got some questions about mobile bolus in the UK and outside the US, can you share a little bit about what our as we from my perspective our international listeners can expect.

Liz Gasser 25:08
Unfortunately, I don’t have an update on timing that I can share with you today, we are working really hard to bring Bob a bolus to our non US markets. And we will update our customers as soon as we’re able to.

Stacey Simms 25:24
Am I correct in the past, I don’t want to rehash everything. But just to be clear that the T Connect program and app as we know it in the US, that’s not going to be what happens. Are you moving on from that internationally? I’m sorry, I can’t remember as I’m asking this,

Liz Gasser 25:37
it will be the mobile bolus app, which some people do know is the T Connect app. So it’ll be an app delivery. But we don’t have an app in our international markets today.

Stacey Simms 25:48
Got it. One of the things I wanted to ask this came up very recently, type pool was just approved by the FDA for their app, their software program. And I think most of us expected this to also be followed by announcement that they would be compatible with Omni pod Insulet products, and perhaps with Medtronic, two partners they’ve had since the beginning. But when I talked to their CEO last week, Howard look, he said no, those agreements are off. They’re not launching with those pumps. He indicated they did have a pump partner, of course, it was with an ace pump. And in the United States, that’s just Tandem. Are you talking to Ty pool? Is this something that that may happen? What

Liz Gasser 26:28
type of oil isn’t currently part of our roadmap today? It’s not an integration that we’re currently working on, as you know, and as we’ve just been talking about, we remain very committed to continuing to evolve control IQ for our customers. And so I’m afraid I can’t add any more color on that one.

Stacey Simms 26:47
Okay, thank you. Thanks for answering that at least, one of the questions I get asked a lot is integration with libre three. And I know that they are not yet I believe they’re not yet considered an ICG M or at least not the United States. Any update on that in terms of possibly working with Tandem?

Liz Gasser 27:02
We don’t actually comment specifically on which version of libre we are working with a launching with, we continue to have a great ongoing relationship with Abbott, we’re integrating with libre. And we are hopeful that we will be able to bring this to market relatively soon, within one to two quarters of Abbott’s approval for use with AD systems in the US.

Stacey Simms 27:24
Before I let you go. Let’s talk about cost for just a moment if we could in the past. Hindemith has had some programs for free software updates. Can you talk at all about the G7 update or the changeover to mobi? If someone’s an existing customer? Are there pathways in place yet for upgrades and things like that?

Liz Gasser 27:44
Yes. A couple of different pieces embedded in that question. So in terms of the software updates, we do offer pre software updates to in warranty customers. And as you know, we have a four year warranty on our pump. And you may ask well, why do you have to be in warranty. And obviously, for us, there’s a lot of compatibility testing that has to happen over a four year period. And so we want to make sure that the pump version can support the software versions can interface with the user’s phones appropriately. And so keeping that current is very important. So we have that program. And then as you look at the movie launch, we we do have a choice program that we are offering, such that users who do buy a T slim today have pathways to a Mobi pump when it launches,

Stacey Simms 28:29
has anything changed. And again, I’m getting a bit into the weeds here. But I just wanna make sure has anything changed in terms of Medicare coverage?

Liz Gasser 28:36
Yeah, well, we are, we are working with others in the industry in terms of changing the thresholds for type two. And that’s a conversation with CMS and Medicare, obviously, in terms of specifically focusing on questioning the ongoing need for something like a C peptide test before a pump can be prescribed, because it’s not necessarily clinically deterministic. So we have those conversations going on.

Stacey Simms 29:01
Is there anything that you want to talk about that I missed before I kind of start wrapping this up?

Liz Gasser 29:06
Well, I think we covered a pretty significant amount of ground. I think all I would just seek to underscore as we wrap up here is, you know, we’re really are very much committed to delivering choice to our customers here, whether it’s through our portfolio of devices, whether it’s through a diversity of infusion sets, whether it’s through multiple CGM integrations, different app and implementations, and it’s ambitious, but we believe it’s important. We don’t, as I said, one size fits all does not work for diabetes. And so we’re excited to keep going we remain committed to continuing to sow our roadmap and looking forward to continuing to deliver great products to our customers.

Stacey Simms 29:50
Well Liz, thank you so much for joining me as you listen, hopefully you haven’t noticed but boy, we had so many technical issues with this. I hung up on lose like five times. So thank you for sticking with me, I really appreciate it. And I appreciate all the information you share today. Thanks so much for joining me.

Liz Gasser 30:05
My pleasure, Stacey. Thank you so much.

Stacey Simms 30:13
You’re listening to Diabetes Connections with Stacey Simms.
Alright, we tried to put a lot of information into that interview and as she said, she will come back and talk more about mobie. Fingers crossed maybe later this year. I’d love to know what you think I’m going to post in the Facebook group Diabetes Connections, the group title loop, I don’t know about you. But when I talked to Howard look about this. Initially, I thought he was saying it would be Tandem. He didn’t say that. I totally inferred that from clues I thought I was getting which I obviously was not getting. It’s a pump. Now that is not yet approved in the United States. Right. pure speculation here would it be the ipso med pump for the but it’s the Kaleido pump, you know, two pumps available in Europe. I also think there’s an outside chance that it could be beta bionics islet. I mean, if there’s a pump in development right now, that’s easy to set up for interoperability. Maybe it comes from the geniuses at beta bionics. So I don’t know we’ve got a long way to go to figure that out.
But I’ll keep you posted. I also have to say, you know, that was Benny’s question that I threw in there about a more aggressive control IQ. But I really did think that was coming. I know they’re working on that. I think that they were three years pest control IQ, which is hard to believe, but I did think there would be an update by now. But PE G7 integration will be fantastic. When that comes. I was gonna say so we can be grateful. But you know what we can be greedy to Let’s Ask for the moon. I don’t think more aggressive bolusing is asking for the moon is certainly we love it. I mean, control IQ has been a homerun for Benny. But yeah, let’s I hope that happens sooner rather than later.
Okay, next up, I want to tell you a little bit about where we are going and what’s going on. But first Diabetes Connections is brought to you by the T1D exchange. I’ve talked about this before. It’s a research study conducted online over time. And it’s open to adults and kids with type one living in the US. Basically, they asked you to complete surveys and sign up for studies on specific topics related to type one. The idea here is to accelerate the discovery and development of new treatments and technologies and support policy or insurance changes that help the T1D community. So by sharing opinions, experiences and data, you can help advance meaningful T1D treatment care and policy, your personal information remains confidential, Your participation is fully voluntary. This is such a good group. And it’s so easy to get started, head on over to the T1D exchange registry at T1D That is T1D why we also have links in the show notes and on the website.
We’ve got some fun stuff coming up back on the road later this month, the JDRF summit in North Carolina is happening in Greensboro, I did see that they were at capacity. There’s a waiting list. So you know, I got a I’m hesitating here, but I’m gonna say it anyway. I think that’s not good. We only have one summit for all of North Carolina now. And if it’s full this far in advance, the need is there. Let’s have another summit or let’s expand the capacity that is not serving this community. Well, if it’s full, and there’s a waiting list, it’s great for JDRF I’m excited, obviously the need is there. But you understand what I’m saying there, the need is not being met. But I am excited to see everybody and talk with Rob. Haven’t seen him in person since the summer. He’s a great advocate. If you haven’t followed him, he does a terrific podcast as well. I am doing a breakout session at this summit called reframe your diabetes, parent brain. It’s all about taking those mom fail moments. And it’s always a mom fail, taking those moments and reframing them to see how we’re not feeling we’re really doing great. So I’m excited about that. It’s more than just putting on some rose colored glasses, I’m going to lead people through an exercise or two that is fun, and can really help you get through to the other side.
And I’m going to be doing two webinars for my local groups. I will put those the newsletters coming up as well, if you want to join this grew out of some questions in my North Carolina groups, but I’m happy to have anybody join. And these are gonna be focusing on diabetes camp, and about a new presentation I have put together called conversations around CGM, I need to catch your name for this. Maybe you guys can help. I’ll put it in the group. It’s basically how to keep remote monitoring from driving us to parent bananas and not getting in the way have a great relationship with your kid. Benny and I knock on wood. We have a terrific relationship. He just came in a minute ago and said hi. Nothing to report just saying hi checking in on me making fun of some stuff around my office like he always does on his way to the gym. And I think a lot of that comes from how we managed our remote monitoring over the years with respect and empathy and humor. So I have a lot to say about that as well, obviously.
All right, thank you as always to my editor, John Bukenas from audio editing solutions. Thank you so much for listening. We do not have a newscast this week. We have switched to every other week for those. And I think that is the right balance. It’s working out really well so far. So I will see you back here on Tuesday for our next long format episode. Until then, I’m Stacey Simms. Be kind to yourself.

Benny 35:25
Diabetes Connections is a production of Stacey Simms media. All rights reserved. All wrongs avenged

Leave a Reply